HINT

Germany
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Chynkiamis

Greece
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

CORFU

Netherlands
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

Harrall

United Kingdom
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Petersen

Faroe Islands
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Andreasson

Sweden
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition
  • Blood sample

UKILD-Long COVID

United Kingdom
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

IMP@LA

France
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

LCV

Italy
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

OpenPROMPT

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Post COVID-19 condition

HemCOV

Sweden
|
2022-2037
  • Adults (18-64 years)
  • General population
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

EuCARE-SCHOOLS

Italy Portugal Mexico
|
2022-2024
  • Adults (18-64 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Nasopharyngeal swab
  • Non pharmacological intervention